tiprankstipranks
Trending News
More News >
Pluri (PLUR)
NASDAQ:PLUR

Pluri (PLUR) AI Stock Analysis

Compare
969 Followers

Top Page

PL

Pluri

(NASDAQ:PLUR)

Rating:50Neutral
Price Target:
$6.00
▲(8.89%Upside)
Pluri's overall stock score reflects significant financial challenges, with high leverage and negative cash flow being primary concerns. The mixed technical indicators suggest some bullish momentum, but caution is advised due to potential overbought conditions. The negative P/E ratio indicates a lack of profitability, impacting valuation negatively. The recent corporate event of regaining Nasdaq compliance is a positive, but financial and profitability issues remain the most significant factors.

Pluri (PLUR) vs. SPDR S&P 500 ETF (SPY)

Pluri Business Overview & Revenue Model

Company DescriptionPluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
How the Company Makes MoneyPluri generates revenue through multiple streams, primarily by developing and commercializing its proprietary cell-based products and therapies. The company monetizes its innovations through partnerships and collaborations with pharmaceutical and biotechnology firms, which may involve licensing agreements, joint ventures, or co-development deals. These partnerships often provide Pluri with upfront payments, milestone payments, and royalties based on the sales of co-developed products. Additionally, Pluri may receive funding from grants and government contracts aimed at supporting research initiatives. The company's financial performance is influenced by its ability to successfully bring products to market, secure strategic partnerships, and achieve regulatory approvals for its therapies.

Pluri Financial Statement Overview

Summary
Pluri faces significant financial challenges across its income statement, balance sheet, and cash flow. The company struggles with profitability, high leverage, and negative cash flow, posing substantial risks to financial stability.
Income Statement
30
Negative
Pluri's income statement reveals persistent challenges, characterized by negative EBIT and EBITDA margins, indicating substantial operational losses. The gross profit margin is exceptionally high in TTM (Trailing-Twelve-Months), but this is offset by significant net losses, resulting in a negative net profit margin. Revenue growth is inconsistent, with occasional increases, but overall revenue remains minimal compared to industry standards.
Balance Sheet
20
Very Negative
The balance sheet highlights financial instability, with a negative stockholders' equity indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, suggesting high leverage and financial risk. The company's equity ratio is unfavorably negative, indicative of a weak financial foundation.
Cash Flow
25
Negative
Cash flow statements show negative free cash flow and operating cash flow, reflecting cash outflows exceeding inflows. The free cash flow to net income ratio is unfavorable, and the operating cash flow to net income ratio is also negative, indicating cash flow issues. Despite efforts to raise financing, the cash flow situation remains challenging.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue1.03M326.00K287.00K234.00K0.0023.00K
Gross Profit478.00K322.00K278.00K-41.36M-50.62M-1.55M
EBITDA-19.76M-20.23M-27.68M-39.43M-48.42M-27.91M
Net Income-20.90M-20.89M-28.32M-41.02M-49.87M-29.35M
Balance Sheet
Total Assets0.0039.53M50.80M68.06M93.54M65.53M
Cash, Cash Equivalents and Short-Term Investments0.0030.24M40.17M55.02M64.95M45.78M
Total Debt6.24M29.61M29.91M28.80M24.58M1.58M
Total Liabilities31.22M34.11M35.50M35.88M36.39M9.43M
Stockholders Equity-4.47M96.00K13.36M30.04M57.15M56.10M
Cash Flow
Free Cash Flow-18.21M-18.34M-23.12M-36.78M-31.28M-26.64M
Operating Cash Flow-17.31M-18.02M-22.86M-36.50M-30.91M-26.37M
Investing Cash Flow193.00K10.58M9.70M11.78M-7.26M-30.46M
Financing Cash Flow18.81M8.84M8.02M7.50M61.40M60.87M

Pluri Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.51
Price Trends
50DMA
4.82
Positive
100DMA
4.64
Positive
200DMA
4.74
Positive
Market Momentum
MACD
0.26
Negative
RSI
60.30
Neutral
STOCH
78.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLUR, the sentiment is Positive. The current price of 5.51 is above the 20-day moving average (MA) of 4.83, above the 50-day MA of 4.82, and above the 200-day MA of 4.74, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 60.30 is Neutral, neither overbought nor oversold. The STOCH value of 78.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLUR.

Pluri Risk Analysis

Pluri disclosed 42 risk factors in its most recent earnings report. Pluri reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Pluri Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.49B0.22-61.87%2.28%16.62%1.08%
50
Neutral
$45.35M-1205.58%203.23%13.57%
48
Neutral
$34.76M-1738.36%-43.55%69.81%
41
Neutral
$27.20M-24.97%38.80%
40
Underperform
$21.24M597.53%88.13%92.45%
39
Underperform
$28.94M-282.07%-220.54%
30
Underperform
$50.14M-2880.11%31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PLUR
Pluri
5.51
-0.12
-2.13%
TPST
Tempest Therapeutics
7.52
-20.69
-73.34%
DARE
Daré Bioscience
2.44
-0.92
-27.38%
CLNN
Clene
3.83
-1.25
-24.61%
NRSN
Neurosense Therapeutics Ltd.
2.09
1.06
102.91%
GDTC
CytoMed Therapeutics Limited
2.25
0.20
9.76%

Pluri Corporate Events

Executive/Board ChangesPrivate Placements and FinancingShareholder Meetings
Pluri’s 2025 Annual Meeting Decisions Announced
Neutral
Jul 3, 2025

On June 30, 2025, Pluri held its 2025 Annual Meeting where shareholders voted on several proposals. Key decisions included the election of directors, ratification of the accounting firm Kesselman & Kesselman, approval of the 2016 Equity Compensation Plan, and the determination that future advisory votes on executive compensation will occur every two years. Additionally, the approval of the exercise of warrants related to a private placement offering was confirmed, excluding shares owned by Mr. Alexandre Weinstein.

The most recent analyst rating on (PLUR) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Pluri stock, see the PLUR Stock Forecast page.

Delistings and Listing ChangesRegulatory Filings and Compliance
Pluri Regains Nasdaq Compliance Before Deadline
Positive
May 8, 2025

Pluri Inc. received a deficiency letter from Nasdaq on November 25, 2024, for not meeting the stockholders’ equity requirement or alternative listing standards. After submitting a compliance plan, Nasdaq granted an extension until May 24, 2025. By May 7, 2025, Pluri regained compliance by maintaining a market value of $35 million for 10 consecutive days, ensuring its continued listing on The Nasdaq Capital Market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 05, 2025